JP2010514781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514781A5 JP2010514781A5 JP2009544162A JP2009544162A JP2010514781A5 JP 2010514781 A5 JP2010514781 A5 JP 2010514781A5 JP 2009544162 A JP2009544162 A JP 2009544162A JP 2009544162 A JP2009544162 A JP 2009544162A JP 2010514781 A5 JP2010514781 A5 JP 2010514781A5
- Authority
- JP
- Japan
- Prior art keywords
- botulinum toxin
- toxin complex
- complex
- attenuated
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010043024 Botulinum Toxins Proteins 0.000 claims 33
- 229940053031 botulinum toxin Drugs 0.000 claims 33
- 230000002238 attenuated Effects 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102100001249 ALB Human genes 0.000 claims 3
- 101710027066 ALB Proteins 0.000 claims 3
- 229940050528 albumin Drugs 0.000 claims 3
- 101710043164 Segment-4 Proteins 0.000 claims 2
- 101700038759 VP1 Proteins 0.000 claims 2
- 101700005460 hemA Proteins 0.000 claims 2
- 108030001720 Bontoxilysin Proteins 0.000 claims 1
- 229940094657 Botulinum Toxin Type A Drugs 0.000 claims 1
- 241000193155 Clostridium botulinum Species 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 1
- 108010069022 botulinum toxin type D Proteins 0.000 claims 1
- 108010069023 botulinum toxin type E Proteins 0.000 claims 1
- 108010069071 botulinum toxin type G Proteins 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000000087 stabilizing Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
Claims (13)
- ボツリヌス毒素を安定化させる方法であって、
ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスを提供するステップと、
HIV−TAT断片又はHIV−TAT断片誘導体であるポリペプチドを提供するステップと、
前記ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスを前記ポリペプチドと組み合わせるステップと
を含む方法。 - ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスがポリペプチドに共有結合で結合される、請求項1に記載の方法。
- ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスがポリペプチドによって非共有結合で安定化される、請求項1に記載の方法。
- HIV−TAT断片が配列番号1による配列を有する、請求項1〜3のいずれかに記載の方法。
- HIV−TAT断片が配列番号2による配列を有する、請求項1〜3のいずれかに記載の方法。
- ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスが、配列番号3による配列を有するポリペプチドを含む、請求項1〜5のいずれかに記載の方法。
- 弱毒化ボツリヌス毒素コンプレックスが、ボツリヌス菌から直接抽出されるボツリヌス毒素コンプレックス中に天然に存在する量と比較して低減された量の血球凝集素タンパク質、非毒素非血球凝集素タンパク質又はその両方を含有する、請求項1〜6のいずれかに記載の方法。
- ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスが、外来の安定剤としてアルブミンを含有する、請求項1〜7のいずれかに記載の方法。
- アルブミンが、天然に存在するボツリヌス毒素コンプレックス中のアルブミンの量の約500倍、400倍、300倍、200倍、100倍、50倍、10倍、5倍、l倍、0.5倍、0.1倍、又は0.01倍に等しい量で存在する、請求項8に記載の方法。
- ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスが、ボツリヌス毒素誘導体、組換えボツリヌス毒素、修飾ボツリヌス毒素、A型ボツリヌス毒素、B型ボツリヌス毒素、C型ボツリヌス毒素、D型ボツリヌス毒素、E型ボツリヌス毒素、F型ボツリヌス毒素、及びG型ボツリヌス毒素からなる群から選択されるボツリヌス毒素を含有する、請求項1〜9のいずれかに記載の方法。
- ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスと、
配列番号2による配列を有するポリペプチドと
を含む、安定化されたボツリヌス毒素組成物。 - ポリペプチドが、ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスと非共有結合で結合している、請求項11に記載の安定化されたボツリヌス毒素組成物。
- ポリペプチドが、ボツリヌス毒素コンプレックス又は弱毒化ボツリヌス毒素コンプレックスと共有結合で結合している、請求項11に記載の安定化されたボツリヌス毒素組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88263206P | 2006-12-29 | 2006-12-29 | |
PCT/US2007/087263 WO2008082889A2 (en) | 2006-12-29 | 2007-12-12 | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013148301A Division JP2014001211A (ja) | 2006-12-29 | 2013-07-17 | Hiv−tatに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010514781A JP2010514781A (ja) | 2010-05-06 |
JP2010514781A5 true JP2010514781A5 (ja) | 2011-02-03 |
Family
ID=39589170
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009544162A Pending JP2010514781A (ja) | 2006-12-29 | 2007-12-12 | Hiv−tatに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法 |
JP2013148301A Pending JP2014001211A (ja) | 2006-12-29 | 2013-07-17 | Hiv−tatに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013148301A Pending JP2014001211A (ja) | 2006-12-29 | 2013-07-17 | Hiv−tatに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20080233152A1 (ja) |
EP (1) | EP2114426A4 (ja) |
JP (2) | JP2010514781A (ja) |
KR (1) | KR20090096735A (ja) |
CN (2) | CN101616682A (ja) |
AR (1) | AR064706A1 (ja) |
AU (1) | AU2007340162B2 (ja) |
BR (1) | BRPI0720730A2 (ja) |
CA (1) | CA2677202A1 (ja) |
CO (1) | CO6220834A2 (ja) |
CR (1) | CR10927A (ja) |
MX (1) | MX2009007068A (ja) |
NO (1) | NO20092779L (ja) |
NZ (1) | NZ598039A (ja) |
TW (1) | TW200848072A (ja) |
WO (1) | WO2008082889A2 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101284710B1 (ko) | 2004-03-03 | 2013-07-23 | 레반스 테라퓨틱스, 아이엔씨. | 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법 |
US9211248B2 (en) * | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
BRPI0608249A2 (pt) * | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
CN101842107B (zh) | 2007-07-26 | 2014-04-23 | 雷文斯治疗公司 | 抗微生物肽,组合物和使用方法 |
PL2271670T3 (pl) | 2008-03-14 | 2015-05-29 | Allergan Inc | Testy aktywności serotypu A toksyny botulinowej oparte na immunologii |
AU2009288088B2 (en) * | 2008-09-03 | 2014-12-04 | Nono Inc. | Agents and methods for treatment of pain |
SG172812A1 (en) * | 2008-12-31 | 2011-08-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations |
PT2413947T (pt) * | 2009-04-01 | 2020-05-28 | Revance Therapeutics Inc | Métodos e composições para tratar condições de pele associadas à hiper-reatividade vascular |
KR102328155B1 (ko) * | 2009-06-25 | 2021-11-17 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
WO2011023213A1 (en) * | 2009-08-28 | 2011-03-03 | Merz Pharma Gmbh & Co. Kgaa | Modified chemodenervating agents |
EP2305290A1 (en) * | 2009-10-05 | 2011-04-06 | Merz Pharma GmbH & Co. KGaA | Salt-free composition comprising an intact Botulinum toxin complex |
JP5932654B2 (ja) * | 2009-10-30 | 2016-06-08 | ルバンス セラピュティックス インク.Revance Therapeutics,Inc. | 治療組成物又は美容組成物を局所的に塗布する装置及び方法 |
US9314514B2 (en) * | 2011-11-09 | 2016-04-19 | Merz Pharma Gmbh & Co. Kgaa | Modified neurotoxins with poly-glycine and uses thereof |
EP2841095A4 (en) * | 2012-03-22 | 2016-01-13 | Revance Therapeutics Inc | PROCESS FOR TREATING WRINKLES IMPRINATING TOPICAL CHEMODENERVATION AGENTS |
WO2014066916A2 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
CN103083651A (zh) * | 2013-01-22 | 2013-05-08 | 南京中医药大学 | 用于外用制剂的穿膜肽介导的肉毒毒素的组合物及其制备方法和应用 |
EP2896864A1 (de) | 2014-01-21 | 2015-07-22 | Siemens Aktiengesellschaft | Verbindungssystem |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
JP6821866B2 (ja) * | 2014-12-08 | 2021-01-27 | ジェイワイエスケイ・スキン・ソリューションズ・プライベイト・リミテッドJYSK Skin Solutions Pte. Ltd. | 担体分子組成物および関連方法 |
KR102607534B1 (ko) * | 2015-12-28 | 2023-11-29 | 오비다트 주식회사 | TATdMt 펩타이드를 포함하는 미백 조성물 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US215412A (en) * | 1879-05-13 | Improvement in ironing-machines | ||
US4078060A (en) * | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4434228A (en) * | 1982-04-20 | 1984-02-28 | Genex Corporation | Immobilization of biological materials in condensed polyalkyleneimine polymers |
US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
US5252713A (en) * | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5420105A (en) * | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US6316003B1 (en) * | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5709861A (en) * | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
US6986893B2 (en) * | 1993-12-28 | 2006-01-17 | Allergan, Inc. | Method for treating a mucus secretion |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
EP0975370B9 (en) * | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
US5985434A (en) * | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
EP1044280A1 (en) * | 1997-12-12 | 2000-10-18 | Onyx Pharmaceuticals, Inc. | SELECTIVE KILLING AND DIAGNOSIS OF p53?+ NEOPLASTIC CELLS |
WO1999042091A2 (en) * | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
US6261679B1 (en) * | 1998-05-22 | 2001-07-17 | Kimberly-Clark Worldwide, Inc. | Fibrous absorbent material and methods of making the same |
MXPA01000271A (es) * | 1998-07-13 | 2002-10-17 | Expression Genetics Inc | Analogo de poliester de poli-lisina como un portador para el suministro de genes, soluble, biodegradable. |
US6280937B1 (en) * | 1998-08-14 | 2001-08-28 | Rigel Pharmaceuticals, Inc. | Shuttle vectors |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
MXPA01004254A (es) * | 1998-10-27 | 2002-04-24 | Mayo Foundation | Metodos para intensificar la curacion de heridas. |
US6627632B2 (en) * | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US7056656B1 (en) * | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
US7008924B1 (en) * | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6730293B1 (en) * | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
EP1210121A2 (en) * | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US20030104622A1 (en) * | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6458763B1 (en) * | 1999-09-17 | 2002-10-01 | Depuy Orthopeadics | Bone sialoprotein-based compositions for enhancing connective tissue repair |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
US7070807B2 (en) * | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
US20040109871A1 (en) * | 2000-01-06 | 2004-06-10 | Pascual David W. | M cell directed vaccines |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
PT1253932E (pt) * | 2000-02-08 | 2005-07-29 | Allergan Inc | Composicoes farmaceuticas de toxina botulinica |
US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US20030215412A1 (en) * | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US20030219462A1 (en) * | 2000-07-21 | 2003-11-27 | Allergan Sales, Inc | Clostridial neurotoxin compositions and modified clostridial neurotoxins |
EP2364734B1 (en) * | 2000-07-21 | 2017-09-06 | ReVance Therapeutics, Inc. | Multi-component biological transport systems |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
US7255865B2 (en) * | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
DE60233137D1 (de) * | 2001-02-16 | 2009-09-10 | Univ R | Transporter mit beabstandeten arginin-teilchen |
CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
AU2002355730B2 (en) * | 2001-07-27 | 2007-09-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
US20030109448A1 (en) * | 2001-11-07 | 2003-06-12 | Crowley Kathleen S. | Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
US7060498B1 (en) * | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
EP1461084A2 (en) * | 2001-12-11 | 2004-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Guanidinium transport reagents and conjugates |
US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
US7635681B2 (en) * | 2002-01-09 | 2009-12-22 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
CA2481479C (en) * | 2002-02-26 | 2012-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
US6688311B2 (en) * | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
JP2005538954A (ja) * | 2002-05-31 | 2005-12-22 | トーマス・ジェファーソン・ユニバーシティ | 分子の経上皮輸送用組成物及び方法 |
US7489812B2 (en) * | 2002-06-07 | 2009-02-10 | Dynamic Digital Depth Research Pty Ltd. | Conversion and encoding techniques |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US7071167B2 (en) * | 2002-11-13 | 2006-07-04 | L'oreal | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines |
US6866856B2 (en) * | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
US20040192754A1 (en) * | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
US8871224B2 (en) * | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
CN1946431B (zh) * | 2004-03-03 | 2011-12-07 | 雷文斯治疗公司 | 用于肉毒毒素的局部施用和透皮递送的组合物和方法 |
KR101284710B1 (ko) * | 2004-03-03 | 2013-07-23 | 레반스 테라퓨틱스, 아이엔씨. | 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법 |
US7691381B2 (en) * | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
CA2799413A1 (en) * | 2004-07-26 | 2006-02-23 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
EP1661912A1 (en) * | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
BRPI0608249A2 (pt) * | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
EP1856139B1 (en) * | 2005-03-03 | 2011-04-27 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
-
2007
- 2007-12-12 BR BRPI0720730-1A patent/BRPI0720730A2/pt not_active IP Right Cessation
- 2007-12-12 KR KR1020097015648A patent/KR20090096735A/ko not_active Application Discontinuation
- 2007-12-12 CN CN200780048690A patent/CN101616682A/zh active Pending
- 2007-12-12 NZ NZ598039A patent/NZ598039A/xx unknown
- 2007-12-12 US US11/955,076 patent/US20080233152A1/en not_active Abandoned
- 2007-12-12 CN CN2012104051075A patent/CN102988995A/zh active Pending
- 2007-12-12 JP JP2009544162A patent/JP2010514781A/ja active Pending
- 2007-12-12 EP EP07869164A patent/EP2114426A4/en not_active Withdrawn
- 2007-12-12 MX MX2009007068A patent/MX2009007068A/es not_active Application Discontinuation
- 2007-12-12 CA CA002677202A patent/CA2677202A1/en not_active Abandoned
- 2007-12-12 AU AU2007340162A patent/AU2007340162B2/en active Active
- 2007-12-12 WO PCT/US2007/087263 patent/WO2008082889A2/en active Application Filing
- 2007-12-21 TW TW096149387A patent/TW200848072A/zh unknown
- 2007-12-28 AR ARP070105981A patent/AR064706A1/es unknown
-
2009
- 2009-07-14 CR CR10927A patent/CR10927A/es unknown
- 2009-07-29 NO NO20092779A patent/NO20092779L/no not_active Application Discontinuation
- 2009-07-29 CO CO09079068A patent/CO6220834A2/es not_active Application Discontinuation
-
2013
- 2013-07-17 JP JP2013148301A patent/JP2014001211A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010514781A5 (ja) | ||
CO6220834A2 (es) | Composiciones y metodos de aplicacion topica y suministro transdermico de toxinas botulinum estabilizadas con fragmentos de polipeptido derivado de hiv-tat | |
JP2014193892A5 (ja) | ||
BR112013010855A2 (pt) | luciferases derivadas de oplophorus, novos substratos de coelenterazina e métodos de uso | |
EA201300455A1 (ru) | Полипептиды с пермеазной активностью | |
NZ606584A (en) | Binding proteins for hepcidin | |
ES2678144T3 (es) | Composiciones relacionadas con SAH y métodos de uso | |
NZ600278A (en) | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto | |
EP2266599A3 (en) | Therapeutic composition with a botulinum neurotoxin | |
MX2011013455A (es) | Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3. | |
JP2015514395A5 (ja) | ||
WO2013098205A3 (en) | Detergent compositions with lipase variants | |
BR112015008673A2 (pt) | composto, composição farmacêutica e método | |
NZ612312A (en) | Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota | |
ATE527345T1 (de) | Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten | |
EA201100071A1 (ru) | Новые композиции и способы | |
UA103602C2 (ru) | АНТИТЕЛО, СПЕЦИФИЧНОЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОГО ИЛИ ЛЕКАРСТВЕННОГО СРЕДСТВА | |
MX2016004579A (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
WO2012163817A3 (en) | Immunogenic composition | |
MX2011008759A (es) | Medios y metodos para fabricar neurotoxina altamente pura. | |
RU2011154363A (ru) | Комбинации клад rrgb пневмококков | |
JP2010532766A5 (ja) | ||
ATE453663T1 (de) | Zusammensetzungen von für pathogene stämme spezifischen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie | |
MX2016006277A (es) | Secuencia de endolisina kz144 modificada. | |
FR2896693B1 (fr) | Composition comprenant plusieurs toxines botuliques |